Oncosil Medical Ltd
ASX:OSL
Oncosil Medical Ltd
ASX:OSL
Price:
0.005 AUD
Market Closed
Updated:
May 2, 2024
Section:
Relative Value
The Relative Value of one
OSL
stock under the Base Case scenario is
0.002
AUD.
Compared to the current market price of 0.005 AUD,
Oncosil Medical Ltd
is
Overvalued by 52%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
OSL
Relative Value
Base Case
0.002
AUD
Overvaluation 52%
Valuation Multiples
Multiples Across Competitors
OSL Competitors Multiples
Oncosil Medical Ltd Competitors
Oncosil Medical Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Oncosil Medical Ltd
ASX:OSL
|
10.5m AUD | 29.4 | -0.9 | -0.5 | -0.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
221.5B USD | 5.2 | 36.9 | 22.8 | 33.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
182B USD | 4.2 | 22.6 | 16.4 | 20.2 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
41.9B USD | 2.8 | 30.9 | 16.8 | 25.9 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
40.4B USD | 6 | 32.7 | 26.1 | 31.4 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
55.6T KRW | 15 | 64.8 | 34.2 | 49.2 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
36.8B CHF | 5.5 | 56.3 | 19.3 | 28.4 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.6B USD | 7 | 33.7 | 23.6 | 26.2 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
26.4B USD | 8.9 | 44.4 | 30.4 | 36.3 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
24.6B USD | 3 | 40.2 | 17.1 | 26.7 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18.7B EUR | 6.9 | 73.5 | 31.7 | 52 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
